Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
Xingyue He(Takeda (United States)), Sai Murali Krishna Pulukuri(Takeda (United States)), Neil Bence(Nurix (United States)), Ryan Chau(Takeda (United States)), Lawrence R. Dick(Millennium Engineering and Integration (United States)), Mike Sintchak(Takeda (United States)), Hugues Bernard(Takeda (United States)), James Minissale(Takeda (United States)), Erik Koenig(Millennium Engineering and Integration (United States)), James E. Brownell(Millennium Engineering and Integration (United States)), Claudia Rabino(Takeda (United States)), He N. Xu(Takeda (United States)), Jianping Guo(Sun Yat-sen University), Teresa A. Soucy(Millennium Engineering and Integration (United States)), Melissa Gallery(Takeda (United States)), Zhigen Hu(Takeda (United States)), Hua Liao(Millennium Engineering and Integration (United States)), Steven Langston(Takeda (United States)), Hirotake Mizutani(Millennium Engineering and Integration (United States)), Jessica Riceberg(Takeda (United States)), Dylan B. England(Takeda (United States)), Kristina Xega(Takeda (United States)), Xiaofeng Yang(Millennium Engineering and Integration (United States)), Zhonghua Yan(Takeda (United States)), Pooja Shah(Takeda (United States)), John Bradley(Gladstone Institutes), Eric S. Lightcap, John Newcomb(Takeda (United States)), Matt O. Duffey(Takeda (United States))
Cited by 228
Related Papers
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
|Nature Reviews Drug Discovery|2010|554
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
|Molecular Cell|2010|461
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
|Nature Medicine|2018|453